‘Not a magic bullet’: Caron CMO weighs promise, limits of GLP-1s for substance use disorder

GLP-1 receptor agonists, originally developed for diabetes and weight loss, are showing promise in reshaping withdrawal management for substance use disorders (SUDs). At Caron Treatment Centers, Dr. Adam Scioli, chief medical officer, reports that these medications are reducing cravings for a range of substances, including alcohol, opioids, and nicotine. Caron has treated over 230 patients with GLP-1s as part of a study in collaboration with Penn State College of Medicine.

Unlike drugs that target specific receptors, GLP-1s work on the brain's reward system, modulating multiple pathways involved in addiction. Patients often experience reduced cravings and better tolerance to treatment, especially those with both metabolic issues and SUDs. However, Dr. Scioli stresses the importance of cautious, informed use, as GLP-1s are not a “magic bullet” and their long-term effects, dosing, and duration still require further research.

Read the Women's Health article here: ‘Not a magic bullet’: Caron CMO weighs promise, limits of GLP-1s for substance use disorder